Patents by Inventor Jakub JAWORSKI

Jakub JAWORSKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BINDING MOLECULES
    Publication number: 20250026829
    Abstract: The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYLGQMINL (SEQ ID NO: 1) in complex with HLA-A24. The invention also relates to the use of such molecules for the treatment of malignant diseases.
    Type: Application
    Filed: September 30, 2024
    Publication date: January 23, 2025
    Inventors: Jakub JAWORSKI, Kate ATKIN, Arnaud TECHINE, Vijaykumar KARUPPIAH, Florence SCHLOSSER, Ana PEREIRA RIBEIRO, Chandramouli CHILLAKURI, Nathaniel LIDDY, Andrew CREESE, Martin EBNER
  • Binding molecules
    Patent number: 12195534
    Abstract: The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of malignant diseases.
    Type: Grant
    Filed: January 5, 2024
    Date of Patent: January 14, 2025
    Assignee: IMMUNOCORE LIMITED
    Inventors: Nicole Mai, Arnaud Techine, Jakub Jaworski, Kate Atkin, Nathaniel Liddy, Vijaykumar Karuppiah, Ana Pereira Ribeiro, Ana Penas, Andrew Creese, Emma Grant, Stephen Harper, Chandramouli Chillakuri, Eduardo Mateos-Diaz, Tamara Aleksic, Pedro Cuadrado Rodenas
  • Binding molecules
    Patent number: 12134647
    Abstract: The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYLGQMINL (SEQ ID NO: 1) in complex with HLA-A24. The invention also relates to the use of such molecules for the treatment of malignant diseases.
    Type: Grant
    Filed: January 5, 2024
    Date of Patent: November 5, 2024
    Assignee: IMMUNOCORE LIMITED
    Inventors: Jakub Jaworski, Kate Atkin, Arnaud Techine, Vijaykumar Karuppiah, Florence Schlosser, Ana Pereira Ribeiro, Chandramouli Chillakuri, Nathaniel Liddy, Andrew Creese, Martin Ebner
  • BINDING MOLECULES
    Publication number: 20240254228
    Abstract: The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PIWIL1 peptide-HLA complex. The invention also relates to the use of such molecules for the treatment of malignant diseases.
    Type: Application
    Filed: January 5, 2024
    Publication date: August 1, 2024
    Inventors: Nicole MAI, Arnaud TECHINE, Jakub JAWORSKI, Kate ATKIN, Nathaniel LIDDY, Vijaykumar KARUPPIAH, Ana PEREIRA RIBEIRO, Ana PENAS, Andrew CREESE, Emma GRANT, Stephen HARPER, Chandramouli CHILLAKURI, Eduardo MATEOS-DIAZ, Tamara ALEKSIC, Pedro CUADRADO RODENAS
  • BINDING MOLECULES
    Publication number: 20240228617
    Abstract: The present invention relates to binding molecules that comprise T cell receptor (TCR) variable domains and which can bind to a PRAME peptide-HLA complex. In particular, the present invention relates to binding molecules that bind to PYLGQMINL (SEQ ID NO: 1) in complex with HLA-A24. The invention also relates to the use of such molecules for the treatment of malignant diseases.
    Type: Application
    Filed: January 5, 2024
    Publication date: July 11, 2024
    Inventors: Jakub JAWORSKI, Kate ATKIN, Arnaud TECHINE, Vijaykumar KARUPPIAH, Florence SCHLOSSER, Ana PEREIRA RIBEIRO, Chandramouli CHILLAKURI, Nathaniel LIDDY, Andrew CREESE, Martin EBNER